Figure 1.

Pharmacogenomics in cancer and overview of this review. (A) Cancer pharmacogenomics and DL. Cancer pharmacogenomics has three interconnected key components: genomics, drugs and patient outcomes and responses. Emerging large data resources are enabling DL-based study of cancer pharmacogenomics and the achievement of precision oncology. (B) Overview of the study. The study sought to comprehensively review data resources of cancer genomics and pharmacogenomics and demonstrate how DL learning can be applied to achieve several major goals of pharmacogenomics and precision oncology.